Trial Profile
Effects of recombinant human Erythropoietin on circulating and intramuscular endothelial progenitor cells, neovascularisation and oxidative metabolism of skeletal muscle in Friedreich's Ataxia.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Nov 2020
Price :
$35
*
At a glance
- Drugs Epoetin beta (Primary)
- Indications Friedreich's ataxia
- Focus Pharmacodynamics; Therapeutic Use
- 28 Nov 2020 Status changed from recruiting to completed.
- 08 Aug 2011 New trial record